CL2013003298A1 - Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. - Google Patents
Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.Info
- Publication number
- CL2013003298A1 CL2013003298A1 CL2013003298A CL2013003298A CL2013003298A1 CL 2013003298 A1 CL2013003298 A1 CL 2013003298A1 CL 2013003298 A CL2013003298 A CL 2013003298A CL 2013003298 A CL2013003298 A CL 2013003298A CL 2013003298 A1 CL2013003298 A1 CL 2013003298A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- methotrexate
- autoimmunity
- administered
- diseases
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229960000485 methotrexate Drugs 0.000 title abstract 2
- 230000005784 autoimmunity Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003298A1 true CL2013003298A1 (es) | 2014-07-25 |
Family
ID=47177257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003298A CL2013003298A1 (es) | 2011-05-16 | 2013-11-15 | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140135337A1 (enExample) |
| EP (2) | EP2709627B1 (enExample) |
| JP (3) | JP6174572B2 (enExample) |
| KR (3) | KR20140040744A (enExample) |
| CN (4) | CN113209288A (enExample) |
| AU (1) | AU2012256281B2 (enExample) |
| BR (1) | BR112013029501A2 (enExample) |
| CA (1) | CA2835819A1 (enExample) |
| CL (1) | CL2013003298A1 (enExample) |
| CO (1) | CO6841993A2 (enExample) |
| DO (1) | DOP2013000268A (enExample) |
| EC (1) | ECSP13013081A (enExample) |
| ES (1) | ES2836823T3 (enExample) |
| GT (1) | GT201300278A (enExample) |
| IL (2) | IL229245B (enExample) |
| MA (1) | MA35165B1 (enExample) |
| MX (1) | MX2013013445A (enExample) |
| MY (1) | MY173304A (enExample) |
| NI (1) | NI201300121A (enExample) |
| PE (1) | PE20140469A1 (enExample) |
| PH (1) | PH12013502256A1 (enExample) |
| PT (1) | PT2709627T (enExample) |
| RU (1) | RU2674036C2 (enExample) |
| SG (1) | SG194802A1 (enExample) |
| TN (1) | TN2013000472A1 (enExample) |
| UA (1) | UA117556C2 (enExample) |
| WO (1) | WO2012158362A1 (enExample) |
| ZA (1) | ZA201308315B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011139379A2 (en) * | 2010-05-06 | 2011-11-10 | Duke University | A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
| AU2012249553A1 (en) | 2011-04-29 | 2013-10-24 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| MX2013013445A (es) | 2011-05-16 | 2014-07-28 | Genzyme Corp | Induccion de tolerancia inmunologica utilizando metotrexato. |
| MX2015015231A (es) | 2013-05-03 | 2016-07-06 | Selecta Biosciences Inc | Métodos y composiciones para mejorar las células t reguladoras de cd4+. |
| KR102631173B1 (ko) * | 2013-06-04 | 2024-01-31 | 셀렉타 바이오사이언시즈, 인크. | 비-면역억제성 항원 특이적 면역요법제의 반복 투여 |
| IL292575A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system |
| IL255010B2 (en) | 2015-04-15 | 2024-01-01 | Regeneron Pharma | Methods of increasing strength and functionality with gdf8 inhibitors |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2018209300A1 (en) * | 2017-05-12 | 2018-11-15 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| WO2021159092A1 (en) | 2020-02-08 | 2021-08-12 | Genzyme Corporation | Compositions and methods for treating pompe disease |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| WO2005085294A1 (ja) | 2004-03-05 | 2005-09-15 | Denki Kagaku Kogyo Kabushiki Kaisha | ヒアルロン酸−メトトレキサート結合体 |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| RU2445975C2 (ru) * | 2006-03-02 | 2012-03-27 | Алексион Фармасьютикалз, Инк. | Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| AU2009302117B2 (en) | 2008-10-08 | 2016-07-28 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis |
| BRPI0921258A2 (pt) | 2008-11-07 | 2018-10-23 | 4Sc Ag | terapia combinatória compreendendo inibidor de dhodh e metotrexato para o tratamento de doença autoimune |
| MX2013013445A (es) | 2011-05-16 | 2014-07-28 | Genzyme Corp | Induccion de tolerancia inmunologica utilizando metotrexato. |
-
2012
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| CR20160278A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, asi como su uso para la preparación de medicamentos | |
| CL2017001364A1 (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. | |
| DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| MX367241B (es) | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| MX370191B (es) | Composiciones y su uso en el tratamiento de la inmunodeficiencia. | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| PE20150190A1 (es) | Formulacion farmaceutica | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| UY36099A (es) | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad | |
| MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
| PH12015502655A1 (en) | Method | |
| BR112015028890A2 (pt) | derivados de piridona para o tratamento de infecções virais e outras doenças | |
| MX389844B (es) | Regimen de dosificacion para interferon pegilado. |